Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate ...
The ARASAFE study showed significant reductions in grade 3-5 adverse events and grade 3-4 neutropenia or death with a 50 ...
Belzutifan, pembrolizumab, and lenvatinib combination showed superior efficacy in advanced ccRCC, with high overall response rates and prolonged progression-free survival. The study supports ...
The NIAGARA trial showed that adding durvalumab to neoadjuvant chemotherapy in MIBC patients did not negatively impact HRQOL outcomes. Significant improvement in event-free survival was observed with ...
Srikala Sridhar, MD, MSc, FRCPC, outlines phase 2 data on avelumab in patients with locally advanced or metastatic penile cancer. The study included a total of 23 patients with a median age of 59 ...
Andrew W. Hahn, MD, details phase 2 efficacy findings on lenvatinib plus everolimus vs cabozantinib in patients with metastatic ccRCC. Data from the phase 2 LenCabo trial (NCT05012371) showed that ...
In this episode of First Assist: GU Oncology Unpacked, host Taylor Goodstein, MD, speaks with Tullika Garg, MD, MPH, FACS, a urologic oncologist at Geisinger Medical Center in Danville, Pennsylvania, ...
Panelists discuss how structure-based biomarkers such as IsoPSA improve risk stratification by distinguishing aggressive disease from indolent cases more effectively than PSA level alone. Panelists ...
Modern visualization tools have reduced fluoroscopy use, enhancing direct visualization in kidney stone procedures. Single-use ureteroscopes offer superior deflection and image quality, though cost ...
An expert discusses how the proposed Centers for Medicare & Medicaid Services (CMS) rule represents an unusual circumstance that benefits smaller private practices by reducing work relative value ...
Muhammed A. Moukhtar Hammad, MBBCh, outlines key findings from a study evaluating testosterone replacement therapy and hearing-related outcomes. Testosterone replacement therapy (TRT) was not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback